Abstract
The number of young diabetics is increasing and therapeutic options for these patients are limited. Glucagon-like peptide-1 (GLP-1) is secreted from the gut after meals and enhances glucose-induced insulin secretion, inhibits glucagon secretion, suppresses appetite, and delays the gastric-emptying rate. GLP-1 analogs are already widely used in the adult population to improve glycemic control and induce weight loss in overweight subjects with type 2 diabetes. The glucose-lowering effects resulting from the inhibition of glucagon secretion and the gastric-emptying rate could be of clinical importance in type 1 diabetes. In this article we review clinical data regarding the use of GLP-1 receptor agonists in youth and address the potential benefits and safety aspects of these compounds. Large scale clinical trials are still needed in the pediatric population.
MeSH terms
-
Adolescent
-
Adult
-
Child
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 2 / drug therapy
-
Female
-
Gastric Emptying / drug effects
-
Glucagon / metabolism
-
Glucagon-Like Peptide 1 / adverse effects
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin / analysis
-
Humans
-
Hypoglycemic Agents / adverse effects*
-
Hypoglycemic Agents / therapeutic use
-
Insulin / metabolism
-
Insulin Secretion
-
Liraglutide
-
Male
-
Pediatric Obesity / complications
-
Pediatric Obesity / drug therapy
-
Randomized Controlled Trials as Topic
-
Receptors, Glucagon / agonists*
-
Receptors, Glucagon / physiology
Substances
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin
-
Receptors, Glucagon
-
Liraglutide
-
Glucagon-Like Peptide 1
-
Glucagon